LEBANON, Ind. (WISH) — Eli Lilly and Company announced Wednesday it will invest an additional $4.5 billion across two of its Lebanon sites, pushing the company’s total state capital expansion commitments since 2020 to more than $21 billion.
The investment covers Lilly Lebanon API, one of the company’s future active pharmaceutical ingredient sites, and Lilly Lebanon Advanced Therapies — the company’s first dedicated genetic medicine manufacturing facility.
Lilly Lebanon Advanced Therapies is designed to support both clinical and commercial production of advanced therapies that target disease at the genetic level…